Literature DB >> 6690108

Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries.

R Ginsburg, M R Bristow, K Davis, A Dibiase, M E Billingham.   

Abstract

We studied quantitative aspects of coronary artery contraction in isolated epicardial coronary ring segments from 49 human hearts. The order of maximal tension developed by drugs in normal calcium (ionized calcium, 1.26 mM) solution was U-44069 (a prostaglandin endoperoxide analog) greater than histamine greater than carbachol greater than serotonin greater than phenylephrine greater than ergonovine. In Ca2+-free solution these same drugs mediated a lesser degree of contraction, which demonstrates that the human coronary artery uses both "intracellular" and "extracellular" calcium in hormone receptor-activated contraction. U-44069, histamine, carbachol, and phenylephrine produced calcium-free/normal calcium maximal responses of 62.9% 48.7%, 39.8%, and 37.2%, respectively. Morphologic characteristics of the atherosclerotic plaques within the vessel lumen and the degree of myocardial dysfunction did not qualitatively alter these contractile responses. However, severely atherosclerotic coronary segments were supersensitive to histamine, but not to carbachol or calcium. In conclusion, the human epicardial coronary artery is a highly reactive vessel that uses at least two calcium pools to couple contraction. Receptor-coupled agonists differ in their abilities to mediate contraction and in the degree to which each calcium pool is used, and the presence of atherosclerosis potentiates the contractile response to histamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690108     DOI: 10.1161/01.cir.69.2.430

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Coronary vasospasm and sumatriptan.

Authors:  B H Stricker
Journal:  BMJ       Date:  1992-07-11

Review 2.  Mechanisms causing myocardial ischaemia.

Authors:  C W Buffington
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

3.  Binding of muscarine receptor antagonists to pig coronary smooth muscle.

Authors:  I Rinner; H N Doods; K J van Charldorp; D Davidesko; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

Review 4.  [Histamine effects on the heart with special reference to cardiac side effects of H2 receptor antagonists].

Authors:  D Baller; H Huchzermeyer
Journal:  Klin Wochenschr       Date:  1989-08-01

5.  The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline.

Authors:  G Berkenboom; M Depierreux; J Fontaine
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

6.  Effect of epinine on tension of human renal arteries.

Authors:  R H Schwinger; C Schulz; K Brixius; M Böhm; J Müller-Ehmsen; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 7.  Current concepts of vascular occlusive disease. The significance of endothelial trauma and smooth muscle cell proliferation.

Authors:  M K O'Malley
Journal:  Ir J Med Sci       Date:  1988-03       Impact factor: 1.568

Review 8.  Newer concepts in the pathogenesis of myocardial ischaemia. Implications for the evaluation of antianginal therapy.

Authors:  B N Singh; K Nademanee; M A Josephson
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

9.  Effects of histamine H1-receptor blockade on respiratory and cardiac manifestation of systemic anaphylaxis.

Authors:  S B Felix; G Baumann; T Hashemi; M Niemczyk; G Ochsenfeld; Z Ahmad; S Shirani; H Blömer
Journal:  Agents Actions       Date:  1991-07

10.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.

Authors:  M A Creager; S J Gallagher; X J Girerd; S M Coleman; V J Dzau; J P Cooke
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.